Introduction to UDCA and Viral Inhibition

Ursodeoxycholic acid (UDCA), a established drug in hepatology, has shown promising UDCA antiviral activity against Porcine Respiratory Coronavirus (PRCV). PRCV represents a genetic variant of the Transmissible Gastroenteritis Virus that specifically targets the respiratory system. While it often results in mild subclinical symptoms, it can also manifest as atypical interstitial pneumonia. Since PRCV serves as a valuable model for human respiratory coronaviruses, identifying effective antagonists like UDCA is vital for modern clinical practice.

Mechanisms Behind UDCA Antiviral Activity

Research indicates that UDCA suppresses viral infection through two primary pathways. First, the molecule directly interacts with the viral envelope, which induces structural disintegration and neutralizes the virus. Second, UDCA acts as a potent immunomodulator in respiratory epithelial cells. It significantly promotes the secretion of Interferon-beta (IFN-β) and enhances the phosphorylation and nuclear translocation of STAT1. Consequently, this upregulates essential interferon-stimulated genes, specifically ISG15 and MX1, which are crucial for the host\'s innate defense. Furthermore, molecular dynamics simulations demonstrate that UDCA embeds into the hydrophobic pocket of the TLR4 dimerization domain. This specific binding triggers the TLR4-IRF3 signaling pathway, which is essential for mounting an effective type I interferon response.

Clinical Insights and Future Outlook

In addition to cellular studies, researchers utilized ex vivo lung tissue slice models to confirm these findings. The study verified that UDCA effectively reduces viral loads and mitigates inflammatory responses within the lung tissue. Moreover, the use of Schaftoside, a known TLR4 signaling inhibitor, completely reversed the antiviral effects of UDCA. This finding underscores the importance of the TLR4-mediated pathway in controlling respiratory viral infections. While UDCA is primarily prescribed for cholestatic liver diseases in India, its ability to modulate the immune response against coronaviruses offers a novel therapeutic perspective for pulmonologists and infectious disease specialists.

Frequently Asked Questions

How does UDCA directly affect the structure of coronaviruses?

UDCA can disrupt the components of the viral envelope, leading to the disintegration of the viral structure even before it infects host cells.

What signaling pathway does UDCA activate to enhance immunity?

UDCA embeds into the hydrophobic pocket of the TLR4 dimerization domain, thereby activating the TLR4-IRF3 signaling pathway to induce the production of IFN-β.

Can UDCA be used for human coronaviruses based on this study?

While this study focused on the PRCV model, the results provide a scientific basis for exploring UDCA as a broad-spectrum antiviral agent for human respiratory coronaviruses.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice. Refer to the latest local and national guidelines for clinical practice.

References

Zhang X et al. Ursodeoxycholic acid inhibits pneumonia caused by PRCV through the activation of TLR4-IRF3 mediated type Ⅰ interferon pathway. Vet Res. 2026 Mar 02. doi: 10.1186/s13567-026-01721-1. PMID: 41772724.

Brevini T et al. FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2. Nature. 2023;615(7950):134-142.

Li J et al. Protective effect of ursodeoxycholic acid on COVID-19 in patients with chronic liver disease. Front Cell Infect Microbiol. 2023;13:1178590.